Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. Our first commercial product, COMETRIQ® (cabozantinib), is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.
In advancing COMETRIQ from discovery to market, we have put in place an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. Areas of expertise include early discovery and preclinical development, clinical development, translational medicine, regulatory affairs, and sales and marketing, among other functions. In addition, we have leveraged our earlier stage capabilities to establish multiple partnerships and collaborations with leading pharmaceutical and biopharmaceutical companies. These partnerships are designed to advance the development of a variety of targeted therapies. Our late-stage development and commercialization teams are focused on educating audiences about COMETRIQ in appropriate patients with progressive metastatic MTC.